Edward C. Jauch, M.D. has been appointed chairman of the Ischemia Care clinical advisory board. Dr. Jauch is a well-respected clinical leader and author of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke. Ischemia Care is an artificial intelligence company pioneering diagnostic blood tests for stroke,
The Ischemia Care clinical advisory board will guide Ischemia Care’s mission to empower clinicians with biological insights that minimize unnecessary invasive testing and raise diagnostic certainty for maximum treatment benefit.
“Ischemia Care is committed to creating a better process to quickly and accurately diagnose the cause of a stroke,” stated Jeff June, CEO of Ischemia Care. “Dr. Jauch is a world-class expert, bringing a deep understanding of stroke care and a diverse set of experiences that will challenge and improve our way of thinking. We look forward to his leadership as we work to simplify hospital workflow and improve patient care.”
Each year $34B is spent in the U.S. related to stroke care.1 In roughly 150,000 cases, the cause of stroke remains undetermined, increasing the risk of secondary stroke.2 The company’s ISCDx test is the first and only blood test that is able to identify the cause of stroke by analyzing patterns of gene expression in whole blood. The test was developed as a result of the Biomarkers of Acute Stroke Etiology (BASE) clinical trial and is available for patients today.
“The unmet need for a simple, reliable diagnostic test to guide the workup of stroke patients is well understood,” noted Dr. Jauch. “Previous efforts have fallen short in terms of either trial execution, scientific development, or commercialization. This technology has the potential to simplify the search for cause and has major implications for hospital workflow and ultimately our ability as clinicians to more effectively manage secondary prevention.”
Dr. Jauch will co-present BASE clinical trial science at the upcoming 2020 International Stroke Conference, February 19-21, in Los Angeles, California during the following sessions:
- RNA Expression for Diagnosis of Stroke Etiology Differentiating Large Artery and Cardioembolic Stroke: Analytical Validation of Testing from the BASE Clinical Trial. A8. Oral Abstract 50.
- RNA Expression Signature to Diagnose Stroke Etiology by Atrial Fibrillation Versus Large Artery Atherosclerosis Cause: a BASE Clinical Trial Analysis. MP6. Poster Tour WMP61/MP61.
- Biology of Stroke: Role of ELL2, GLIPR1, MAPKAPK3 Genes in Identifying Atrial Fibrillation Cause of Stroke. MP19. Poster Tour TMP100/MP100.
The ISCDx test will also be on display at Ischemia Care’s booth, #503.
Ed Jauch, M.D., Misson Health – Asheville, North Carolina
Dr. Jauch is well known in the field of stroke research, leading or participating in numerous Phase II and III clinical stroke trials over the past 20 years. He served as the Chair of Stroke Council for the American Heart Association/American Stroke Association (AHA/ASA) and primary author of the 2013 Acute Ischemic Stroke guidelines. He is a coauthor on the flagship AHA/ASA guidelines for telemedicine use in stroke, primary prevention of stroke, prehospital care of stroke, and stroke systems of care.
References
- https://www.cdc.gov/stroke/facts.htm
- Saver, J. Cryptogenic Stroke. NEJM. May 26, 2016.